Orphan medicines: special treatment required?: case study 3: Glivec and chronic myeloid leukaemia
- Document type
- Case study
- Corporate author(s)
- 2020health (Think tank)
- Date of publication
- 1 November 2012
- Health Services
- Social welfare
- Material type
Download (124KB )
This case study on the drug Glivec and treatment of chronic myeloid leukaemia accompanies a report that examines the evidence to see if there are ways of improving decision making on treatments for people with rare diseases in the NHS. Glivec (imatibib) is an anticancer medicine, manufactured by Novartis. Glivec has been shown in clinical trials to improve clinical outcomes for patients with chronic myeloid leukaemia (CML) in terms of surrogate outcome measures for survival, including: overall haematological and cytogenetic response rates, and progression-free survival. Glivec was the first in a new class of cancer drug, resulting in reductions in the uncontrolled proliferation of white blood cells which occurs in CML.
Glivec was awarded orphan drug designation for its use in CML and approved for use by the European Medicines Agency in 2001. Glivec was therefore one of the earliest products to be able to benefit from incentives under the Orphan Drug Legislation.
Related to Health Services
Report on economic growth and austerity in Ireland
Report on health spending and austerity
Variation in end of life hospital spending in England: evidence from linked survey and administrative data
Working Paper on healthcare spending
Related to 2020health
This report uses literature data, observations and discussions to frame a new approach to understanding the nature and implications of health-system avoidance by individuals who choose to remain ignorant
This report finds that the over 65s made up 17% of the population in 2010, up from 15% in 1985, with projections indicating a rise to 23% by 2035.Exponential growth of an aging population indicates
This report by the Foresight Project aims to ensure that the optical sector is better equipped to understand directions in technology, ocular medical developments and demographics in the years up to 2030.
Current political, economic and social discourse on obesity in the UK illuminates the great complexities and myriad socio-economic considerations that inform people’s health, diets, and health seeking